Design Therapeutics, Inc.DSGNNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +0.94% | +0.48% | +0.54% | +0.58% | +1.14% |
| Weighted Average Shares Diluted Growth | +0.94% | +0.48% | +0.54% | +0.58% | +1.14% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | -11.80% | -16.17% | -3.58% | +17.13% | +32.78% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -12.96% | -14.82% | -17.32% | -19.06% | -10.27% |
| Book Value per Share Growth | -13.63% | -15.85% | -18.89% | -21.35% | -13.22% |
| Debt Growth | -23.48% | -25.61% | -28.01% | -30.89% | -72.37% |
| R&D Expense Growth | +10.40% | +59.22% | +51.84% | +22.84% | +10.43% |
| SG&A Expenses Growth | +10.42% | +9.61% | +28.80% | +8.05% | +4.56% |